GlaxoSmithKline Plc (GSK) has issued 1.25% international bonds due May 2026 in a public offering to raise ‎€1bn ($1.19bn).

The company has also issued 1.75% international bonds due May 2030, and international bonds due May 2020 in a public offering to raise €750m ($897.11m) and €750m ($897.11m) respectively.

The company has appointed Barclays Capital Inc BNP Paribas Securities Corp, Citigroup Global Markets Inc, and Mizuho Financial Group Inc as book runners for the transaction.

Clearstream Banking SA and Euroclear Bank SA acted as depository to the company for the transaction.

US-based Ligand Pharmaceuticals Incorporated has plans to issue convertible senior notes due 2023 in a private placement to raise $650m.

Institutional investors will subscribe to the placement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The initial buyers will be granted a 13-day option to purchase up to $100m-worth of additional notes.

“The initial buyers will be granted a 13-day option to purchase up to $100m-worth of additional notes.”

Ligand and the initial purchasers will determine the initial conversion rate, interest rate and certain other terms of the notes.

Ligand plans to use proceeds for the cost of certain convertible note hedge transactions, to repurchase $50m worth of Ligand’s common stock, and to acquire or invest in new businesses, companies, products, and technologies.

The company also plans to use funds for working capital and other general corporate purposes, including research and development (R&D) activities.

Catalent Pharma Solutions LLC has signed an agreement with Valerius Biopharma AG to develop and produce the latter’s biosimilar products.

Catalent will offer its proprietary GPEx technology for cell line development and support cGMP manufacturing activities between phase one and commercial development at its production facility located in Madison, Wisconsin, as part of the agreement.

Based in the US, Catalent is a pharmaceutical company and a subsidiary of Catalent Inc.

The agreement enables both the companies to develop and produce biosimilar products using proprietary GPEx technology.